Endo International acquires BioSpecifics Technologies Corp. at $88.5 per share. BioSpecifics has developed and patented injections for the treatment of Dupuytren's contracture and Peyroni's disease, which are currently sold to Endo under the XIAFLEX brand, paying royalties to BioSpecifics. The deal is expected to be closed by the end of 2020.
Endo International acquires BioSpecifics Technologies Corp. at $88.5 per share. BioSpecifics has developed and patented injections for the treatment of Dupuytren's contracture and Peyroni's disease, which are currently sold to Endo under the XIAFLEX brand, paying royalties to BioSpecifics. The deal is expected to be closed by the end of 2020. 
English (US) 